Janus kinases (JAKs), members of the non-receptor protein tyrosine kinase family, are key components of signaling pathways in hematopoiesis and cellular immunity. JAKs are associated with the cytoplasmic domains of cytokine receptors and, upon cytokine-mediated receptor dimerization or rearrangement of pre-existing receptor dimers, are activated through trans-phosphorylation. Activated JAKs phosphorylate STATs (signal transducers and activators of transcription), which translocate to the nucleus and serve as transcriptional activators. Mammalian JAKs (JAK1-3 and TYK2) possess four domains in common: an N-terminal FERM domain, an SH2-liske domain, a pseudokinase domain, and a C-terminal tyrosine kinase domain. Extensive biochemical data, as well as gain-of-function mutations that cause myeloproliferative neoplasms (MPNs) in humans, have implicated the pseudokinase domain of JAKs as crucial for maintaining a low basal level of tyrosine kinase activity. There is also evidence that the pseudokinase domain plays a positive regulatory role in normal JAK2 activation (by cytokine) and in the hyperactivity of mutants such as V617F, the most prevalent MPN mutant. The first goal of this proposal is to employ structural, biochemical, and computational approaches to elucidate the molecular mechanisms that govern JAK2 activation, both normally (through cytokine) and pathogenically (through mutation), and receptor interaction. A second goal is to use this structural knowledge to discover novel allosteric inhibitors that could selectively inhibit JAK2 V617F. Such compounds would have potential use as therapeutics in the treatment of MPN patients.

Public Health Relevance

Activating mutations in the JAK family (JAK1-3, TYK2) of protein tyrosine kinases are causative for numerous types of myeloproliferative neoplasms in humans, including polycythemia vera and primary myelofibrosis, and are also linked to several leukemias. Most of these mutations map to the so-called pseudokinase domain of JAKs, with V617F in JAK2 being the most prevalent disease mutation. We will employ x-ray crystallography and biochemical approaches to elucidate the molecular mechanisms governing JAK2 regulation by the pseudokinase domain, and utilize this structural information to discover novel small molecules that selectively inhibit the MPN mutant V617F.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI101256-04
Application #
9394769
Study Section
Cellular and Molecular Immunology - A Study Section (CMIA)
Program Officer
Singleton, Kentner L
Project Start
2015-07-01
Project End
2019-12-31
Budget Start
2018-01-01
Budget End
2018-12-31
Support Year
4
Fiscal Year
2018
Total Cost
Indirect Cost
Name
New York University
Department
Pharmacology
Type
Schools of Medicine
DUNS #
121911077
City
New York
State
NY
Country
United States
Zip Code
10010
Silvennoinen, Olli; Hubbard, Stevan R (2015) Molecular insights into regulation of JAK2 in myeloproliferative neoplasms. Blood 125:3388-92
Hammarén, Henrik M; Ungureanu, Daniela; Grisouard, Jean et al. (2015) ATP binding to the pseudokinase domain of JAK2 is critical for pathogenic activation. Proc Natl Acad Sci U S A 112:4642-7